Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies

Vascular Medicine

Volumn 11, Issue 3, 2006, Pages 141-145

  Brass, Eric P ^a   Hiatt, William R ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Claudication; Clinical trials; Morbidity; Mortality; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; RAMIPRIL;

ANKLE BRACHIAL INDEX; ARTERY DISEASE; CARDIOVASCULAR DISEASE; CLAUDICATION; CLINICAL TRIAL; DEATH; HUMAN; INFORMATION PROCESSING; MORBIDITY; MORTALITY; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; TREADMILL EXERCISE; TREATMENT OUTCOME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; INTERMITTENT CLAUDICATION; LINEAR MODELS; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK FACTORS;

EID: 33846199993     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863x06069513     Document Type: Review

References (29)

1. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
2. McDermott MM, Mehta S, Liu K et al. Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. J Gen Intern Med 1999; 14: 173-81.
3. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation 1995; 92: 614-21.
4. Brass EP, Lewis RJ, Lipicky R, Murphy J, Hiatt WR. Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk. Clin Pharmacol Ther 2006; 79: 165-72.
5. Criqui MH, Larger RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-86.
6. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg 1999; 12: 123-37.
7. Muluk SC, Muluk VS, Kelley ME et al. Outcome events in patients with claudication: a 15-year study in 2777 patients. J Vasc Surg 2001; 33: 251-57; discussion 257-58.
8. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
9. Ostergren J, Sleight P, Dagenais G et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25: 17-24.
10. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-86.
11. Money SR, Herd JA, Isaacsohn JL et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27: 267-74; discussion 274-75.
12. Beebe HG, Dawson DL, Cutler BS et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159: 2041-50.
13. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999; 34: 1618-24.
14. Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000; 102: 426-31.
15. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-30.
16. Hiatt WR, Regensteiner JG, Creager MA et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001; 110: 616-22.
17. McGrath C, Robb R, Lucas AJ et al. A randomised, double blind, placebo-controlled study to determine the efficacy of immune modulation therapy in the treatment of patients suffering from peripheral arterial occlusive disease with intermittent claudication. Eur J Vasc Endovasc Surg 2002; 23: 381-87.
18. Lederman RJ, Mendelsohn FO, Anderson RD et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359: 2053-58.
19. Rajagopalan S, Mohler ER 3rd, Lederman RJ et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-38.
20. Mohler ER 3rd, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin 12 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003; 41: 1679-86.
21. Hiatt WR, Klepack E, Nehler M et al. The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease. Vasc Med 2004; 9: 271-77.
22. Hiatt WR, Hirsch AT, Cooke JP, Olin JW, Brater DC, Creager MA. Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Vasc Med 2004; 9: 18-25.
23. Gresele P, Migliacci R, Di Sante G, Nenci GG. Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. CRAMPS Investigator Group. Cloricromene Randomized Arteriopathy Multicenter Prospective Study. Vasc Med 2000; 5: 83-89.
24. Castano G, Mas R, Roca J et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology 1999; 50: 123-30.
25. Nenci GG, Gresele P, Ferrari G, Santoro L, Gianese F. Treatment of intermittent claudication with mesoglycan - a placebo-controlled, double-blind study. Thromb Haemost 2001; 86: 1181-87.
26. Messa GL, Gelso E. Heparan sulfate in the treatment of intermittent claudication: results of a randomized, double-blind, placebo-controlled multicenter trial. Drugs Exp Clin Res 2002; 28: 37-48.
27. Strandness DE Jr, Dalman RL, Panian S et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg 2002; 36: 83-91.
28. Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-75.
29. Burns P, Wilmink T, Fegan C, Bradbury AW. Exercise in claudicants is accompanied by excessive thrombin generation. Eur J Vasc Endovasc Surg 2003; 26: 150-55.